OCUGEN INC OCGN 深 滬
已收盤 08-01 16:00:00 美东时间
0.9936
-0.036
-3.53%
華盛通- 最 高1.02
- 今 開1.00
- 成交量 443.88万股
- 最 低 0.9425
- 昨 收 1.03
- 總市值 2.90亿
- 52周最高 1.40
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 0.515
- 委 比 -37.75%
- 總股本 2.92亿
- 歷史最高 18.77
- 量 比 2.02
- 振 幅 7.52%
- 歷史最低 0.17
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ocugen Reports Progress in Gene Therapy Trials
Ocugen Inc ( ($OCGN) ) has released its Q2 earnings. Here is a breakdown of the...
08-02 12:22
Ocugen Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $1.373M Beat $350.000K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 19.35 percent. This is a 25 percent decrease over losses of $(0.04) per share from the same
08-01 21:54
Earnings Scheduled For August 1, 2025
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBUC) is expect...
08-01 16:32
A Peek at Ocugen's Future Earnings
Ocugen (NASDAQ:OCGN) is set to give its latest quarterly earnings report on Fri...
08-01 02:01
Ocugen Wins Dismissal of Securities Lawsuit
An update from Ocugen ( ($OCGN) ) is now available. On July 29, 2025, the U.S. ...
07-31 05:18
U.S. Court Granted Ocugen's Motion To Dismiss Securities Class Action Lawsuit
-SEC Filing
07-31 05:13
苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
07-28 20:40
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
<p>Ocugen, Inc. announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance and internal expertise as it aims to submit three BLAs in the next three years. Three renowned retinal surgeons, Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Arshad M. Khanani, MD, MA, FASRS, have joined the Retina SAB, along with existing members. Additionally, Vijay Tammara, PhD, has been appointed Chief D...
07-21 11:30
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
Ocugen, Inc., a leader in gene therapies for blindness, will-host a conference call and live webcast on August 1, 2025, at 8:30 a.m. ET to discuss its Q2 2025 financial results and provide a business update. A replay will be available on its investor site. The company specializes in gene-agnostic modifier therapies targeting complex eye diseases.
07-17 10:30
CEL-SCI announces pricing of $5.7 million offering
CEL-SCI (NYSE:CVM) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share,...
07-12 03:04
